ILK在异丙肾上腺素诱导大鼠心肌肥厚组织中的表达

目的探讨心肌肥厚发生发展过程中ILK的表达特征。方法在大鼠背部皮下分别注射7、28和56 d异丙肾上腺素(ISO),判定心肌肥厚指标,利用免疫组织化学和免疫印迹技术,观察ILK在肥厚左心室肌中的表达。结果 ILK主要表达于心肌细胞胞膜和内皮细胞。与对照组相比,ISO组ILK阳性表达明显增强。随着造模时间的延长,肥厚心肌中ILK的表达含量逐渐升高。Western blot图像分析结果显示:ISO各实验组大鼠左心室心肌组织中的ILK蛋白表达带均强于对照组(P<0.01),7、28和56 d组间比较差异有统计学意义(P<0.05)。结论 ILK与心肌肥厚的发生和发展有关,心肌肥大越重,ILK含量增加越高。     

多囊蛋白2在肾组织和体外培养细胞中的表达

常染色体显性多囊肾病(autosomaldominantpolycystickid neydisease ,ADPKD)是一种常见的单基因遗传性疾病。它以双肾多发性囊肿为特征,囊肿不断形成和进行性增大,导致肾功能下降,到6 0岁时大约有5 0 %的患者进展至终末期肾衰。目前,已知引起ADPKD的基因主要有两个,分别命名为P     

辛伐他汀对高脂血症大鼠肾小管间质病变及其ILK表达的影响

目的： 探讨辛伐他汀对高脂诱导的大鼠肾组织整合素连接激酶（ILK）的表达及其对肾小管间质损害的影响。方法：54只Wistar大鼠随机分3组：高脂饮食组给予高脂饲料喂养,辛伐他汀组用高脂饲料喂养同时,给予辛伐他汀10 mg·kg-1·d-1干预,正常对照组给予正常饮食。实验第4周、10周及20周后各组分别随机取6只大鼠处死,取血清及肾组织标本,测定血脂水平、HE染色观察大鼠肾小管-间质损害程度,用Western印迹及免疫组化染色观察大鼠肾间质ILK的表达。结果：与正常对照组比较,从第4周开始,高脂饮食组及辛伐他汀组大鼠血脂水平升高,肾小管上皮细胞逐渐出现融合、浊肿、坏死,肾小管萎缩,管腔结构消失,炎症细胞浸润,间质纤维化,残余的小管上皮出现空泡变性,管壁变薄,代偿性扩张,肾组织ILK的表达明显增加,且随着喂养时间延长,上述指标变化更加明显;而辛伐他汀组与相同时点高脂饮食组比较,上述指标均明显减轻。结论: 高脂饮食大鼠存在有明显的肾小管间质损害,并可能与肾组织ILK表达明显增多密切相关,辛伐他汀可能通过抑制肾小管间质ILK的表达,减轻高脂饮食大鼠肾小管间质病变。     

法尼醇X受体表达与胰腺癌患者预后及病理分期相关

目的探索法尼醇X受体(FXR)与胰腺癌患者临床分期及生存时间的相关性。方法培养8株胰腺癌细胞,用Western blot和real-time PCR检测FXR在胰腺癌细胞中的表达水平。临床收集5名正常胰腺组织和50例胰腺癌组织。用免疫组化检测FRX在组织中的蛋白表达水平;根据FXR的不同表达水平分为FXR低和高表达组,并且与胰腺癌患者临床资料进行相关性分析;应用Kaplan-Meier和log-rank方法进行生存分析,COX比例风险回归模型进行多因素分析,研究FXR表达水平与胰腺癌患者预后的相关性。结果 FXR在胰腺癌细胞及胰腺癌组织中呈不同程度的高表达,而且与胰腺癌组织病理G分期密切相关(P<0.05);FXR表达水平与病理G分期均与胰腺癌患者的生存时间具有显著相关性,FXR高表达患者的生存时间明显长于FXR低表达患者的生存时间(P<0.05)。结论胰腺癌患者FXR表达水平与病理G分期密切相关,FXR表达水平和病理G分期均是胰腺癌患者独立的预后因素。     

基因沉默ILK对胰腺癌细胞Panc-1细胞增殖、凋亡与侵袭的影响

目的探讨基因沉默整合素连接激酶(ILK)对胰腺癌细胞(Panc-1)细胞增殖、凋亡与侵袭的影响。方法培养胰腺癌Panc-1细胞,构建ILK-specific shRNA慢病毒载体后对Panc-1细胞进行转染,qPCR与Western Blot方法验证干扰基因片段的有效性,MTT实验检测转染后胰腺癌细胞增殖能力的变化,流式细胞仪检测转染后胰腺癌细胞周期的变化,Transwell实验检测转染后胰腺癌细胞侵袭能力的改变。结果成功构建siRNA-ILK慢病毒载体,转染组细胞的ILK mRNA及蛋白表达明显低于空病毒组及阴性对照组。基因沉默ILK的胰腺癌Panc-1细胞增殖能力显著降低,停滞在G0/G1的细胞数显著增多,G2/M期细胞数明显减少,侵袭能力显著降低(P0.01)。结论基因沉默ILK能抑制胰腺癌细胞Panc-增殖与侵袭能力,并促进凋亡。     

膀胱癌中整合素连接激酶及相关信号转导通路分子的表达及意义

目的 探讨整合素连接激酶(integrin linked kinase,ILK)及相关信号转导通路分子在膀胱癌中的表达及其临床意义.方法 采用免疫组化SP法检测47例膀胱癌及25例癌旁组织中ILK、AKT及β-catenin的表达.结果 ILK、AKT和β-eatenin在膀胱癌和癌旁组织中的阳性率分别为53.19％和12.00％、44.68％和20.00％、48.94％和12.00％,且差异均有显著性(x2=11.651,x2=4.309,x2=9.650,P＜0.05).同时,ILK、AKT及β-catenin在高分化膀胱癌组中的表达明显低于低分化癌组,差异有统计学意义(P＜0.05).AKT、β-catenin和ILK在膀胱癌中的表达均呈正相关.结论 ILK、AKT及β-catenin的异常表达在膀胱癌的恶性进展中起重要作用,三者联合检测可能为揭示膀胱癌发生、发展的有关机制提供理论依据.ILK、AKT及β-catenin的异常表达与膀胱癌的临床病理分级密切相关,可能参与膀胱癌的发生、发展,联合检测有助于判断膀胱癌的恶性程度.     

Gab2在结直肠癌组织中的表达及其意义

目的:探讨Gab2在结直肠癌组织中的表达及其意义。方法:应用免疫组化方法检测78例结直肠癌及46例癌旁正常组织中Gab2的表达水平,并结合临床病理学资料进行统计学分析,Western blot方法检测10对结直肠癌组织及相对应的癌旁正常组织中Gab2的表达状况。结果:免疫组化检测结果显示78例结直肠癌组织中Gab2蛋白表达阳性率为53.85%,而癌旁正常组织中Gab2蛋白多不表达或弱表达,两组结果比较差异有显著性(P0.001);Gab2蛋白在结直肠癌中的表达与肿瘤TNM分期及有无淋巴结转移呈正相关(P0.05),与肿瘤大小、分化程度无明显相关性(P0.05);Western blot检测结果显示结直肠癌组织中Gab2蛋白表达显著高于相对应的癌旁正常组织(P0.05)。结论:Gab2在结直肠癌组织中过表达,可能在结直肠癌的发生发展中起重要作用。     

整合素连接激酶和β1整合素在大鼠烫伤创面愈合过程中表达的实验研究

目的探讨大鼠烫伤创面愈合过程中整合素连接激酶（ILK）和β1整合素的表达以及在创面愈合中的作用。方法健康雌性SD大鼠18只,随机选取其中15只作为实验组,建立深Ⅱ度烫伤模型,另外3只为对照组,不做处理。实验组分别于烫伤模型建立后第1、5、10、15、20天随机选取3只大鼠,切取背部两侧全层创面,运用免疫组织化学的方法检测创面中ILK、β1整合素的表达。对照组取背部正常皮肤作为对照。结果实验组烫伤后第5、10、15天大鼠烫伤创面中ILK的表达明显高于对照组和实验组烫伤后第20天（P〈0.05）;创面中β1整合素的表达在烫伤后第5天明显高于对照组（P〈0.05）,实验组烫伤后第10、15天则明显高于对照组和实验组烫伤后第20天（P〈0.05）。结论ILK、β1整合素在大鼠创面愈合过程中表达明显增加,ILK可能通过参与整合素信号通路,在调节创面细胞的增生以及细胞与ECM相互作用中扮演着重要的角色。     

特异性ILK siRNA对膀胱癌EJ细胞EMT及移植瘤生长的影响

目的研究整合素连接激酶(ILK)特异siRNA沉默ILK基因对膀胱癌EJ细胞上皮间质转化(EMT)及移植瘤生长的影响。方法用特异性ILK siRNA表达载体p Gensil-1siRNA1质粒和对照质粒p Gensil-1siRNA3稳定转染EJ细胞,实验分为EJ siRNA组、EJ vector组和EJ细胞组;激光共聚焦显微镜下观察细胞骨架;Western blot检测p-AKT、p-GSK-3β蛋白的表达;细胞免疫荧光检测p-AKT、p-GSK-3β的表达;用免疫荧光检测整合素连接激酶和核糖核酸酶抑制因子在EJ细胞中的共定位;MTT法检测细胞增殖;流式细胞术检测细胞周期;建立裸鼠移植瘤模型,肿瘤和肺组织切片HE染色,免疫组化检测瘤组织中ILK、RI、NM23-H1和E-cadherin蛋白的表达;免疫荧光检测p-AKT、p-GSK-3β和CD31蛋白的表达。结果 EJ siRNA组细胞运动能力减弱;EJ siRNA组p-AKT、p-GSK-3β蛋白表达明显降低(P0.05);MTT法结果提示实验组细胞增殖明显受到抑制;下调ILK通过阻滞G0/G1期抑制细胞增殖;下调ILK抑制膀胱癌EJ细胞移植瘤生长转移。结论特异性ILK siRNA可以改变EJ细胞特性,抑制EMT的发生,引起增殖侵袭能力下降。     

卵巢癌中MSI2蛋白表达及与临床病理特征的关系

目的 探讨卵巢癌组织中RNA结合蛋白MSI2的表达及临床意义.方法 采用免疫组化及Western blot法检测卵巢癌组织及配对癌旁正常卵巢组织和输卵管组织中MSI2的表达部位和表达量,分析MSI2表达与卵巢癌临床病理特征的关系.利用Kaplan-Meier生存曲线评估患者的总生存率,Cox回归模型分析MSI2表达的临...     

High expression of integrin-linked kinase predicts aggressiveness and poor prognosis in patients with gastric cancer

Integrin-linked kinase (ILK), an intracellular serine/threonine protein kinase, has been reported to be highly expressed in many human malignancies, including gastric cancer. However, the prognostic significance of ILK expression in gastric cancer remains to be elucidated. In the present study, ILK expression in 95 gastric tumor tissues and 30 adjacent non-cancerous gastric mucosa was evaluated by immunohistochemistry and correlated with clinicopathological characteristics and patients’ outcome. The results showed that high ILK expression was observed in 47.4% (45/95) of gastric cancer tissues, but only in 20.0% (6/30) of adjacent gastric mucosa. Clinicopathological analysis indicated that high ILK expression was significantly associated with poor tumor differentiation (P = 0.024), advanced TNM stage (P = 0.006), tumor invasion (P = 0.001), and lymph node metastasis (P = 0.014). Kaplan–Meier survival curves demonstrated that patients with high ILK expression had substantially shorter overall survival that those with low ILK expression (P = 0.043, log-rank test). Furthermore, Cox multivariate regression analysis identified ILK expression as an independent prognostic factor for overall survival of gastric cancer patients (hazard ratio, 1.95; 95% confidence interval, 1.02–3.13; P = 0.026). In conclusion, our data suggest that ILK may contribute to the malignant progression of gastric cancer and serve as a novel prognostic indicator for gastric cancer patients.     

Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients

The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains dismal even after complete resection, with most recurrences occurring within 1–2 years postoperatively. Adenosine triphosphate (ATP)‐binding cassette (ABC) transporters have been demonstrated to play major roles in multidrug resistance (MDR) of cancers. In this study, we evaluated the expression statuses and the clinical significance of MDR1 (ABCB1), MDR‐associated proteins (MRPs/ABCC) 1, 2 and 3, and breast cancer resistance protein (BCRP/ABCG2) in 67 surgically resected PDACs by immunohistochemistry. MDR1, MRP1, MRP2, MRP3 and BCRP were expressed in 35 (52.2%), 56 (83.6%), 61 (91.0%), 49 (73.1%) and 49 (73.1%) out of 67 cases, respectively. The expression statuses of the MDR‐related proteins were positively correlated with each other (P < 0.05). Tumors expressing MRP1 (P= 0.015), MRP2 (P= 0.022) and MRP3 (P < 0.001) demonstrated more frequent perineural invasion. MDR1 expression was significantly correlated with lymphatic invasion (P= 0.047). High BCRP expression in PDAC was a significant prognostic factor for early tumor recurrence (HR = 2.43, P= 0.003) and poor survival (HR = 2.63, P= 0.001). MDR‐related proteins are frequently expressed in PDAC, and high BCRP expression is a significant independent predictor for early recurrence and poor survival. Immunohistochemical analysis for BCRP expression in PDAC may be a useful test in identifying a subgroup of patients with a poor prognosis.     

The epidermal growth factor receptor in human pancreatic cancer.

The epidermal growth factor receptor (EGFR) and its ligands are thought to be important in the control of proliferation of many epithelial systems, including the exocrine pancreas. Abnormalities in expression of two of the known ligands of the EGFR, transforming growth factor alpha and epidermal growth factor, occur frequently in ductal adenocarcinoma of the human pancreas. We have examined an archival series of cases of pancreatic pathology for expression of the EGFR using the anti-EGFR antiserum 12E and found that there is almost ubiquitous overexpression of EGFR in pancreatic cancer and in chronic pancreatitis. Southern blot analysis showed no evidence of amplification or rearrangement of the EGFR gene. We conclude that an autocrine loop involving the EGFR system may be involved in the genesis of both neoplasia and reactive hyperplasia of pancreatic ductal epithelium.     

Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines

Tumours evade immune recognition and destruction through loss or down-regulation of expression of antigen processing and antigen-presenting molecules such as the human leucocyte antigen (HLA class I) and transporter for antigen presentation (TAP). This study examined the expression of HLA class I, class II and TAP in human pancreatic carcinoma tissue and 19 immortalized pancreatic cancer lines using a panel of antibodies directed against allele-specific as well as monomorphic determinants of these molecules. In tissue samples, reduction or loss of HLA class I and TAP was observed in 76% of cases, loss or down-regulation of TAP expression in 53%. In pancreatic cell lines down-regulation or loss of class I and TAP expression was also observed frequently. However, reductions in class I and TAP expression were reversible upon exposure to interferon-gamma in vitro, suggesting a regulatory rather than structural defect in these genes. De novo class II expression was observed in 26% of tumours and 42% of cell lines and may reflect the differentiation status of the cells. The high rate of class I and TAP loss has implications for immunotherapy strategies for pancreatic cancer, as such changes could facilitate a selective growth advantage for malignant cells. However, the reinduction of expression of these molecules with cytokines such as interferon-gamma may ultimately allow their cytotoxic T cell-mediated destruction.     

siRNA-ILK慢病毒载体的构建

目的构建RNA干扰整合素连接激酶(ILK)基因的慢病毒载体并转染胰腺癌细胞(Panc-1),并验证其干扰有效性。方法对胰腺癌Panc-1细胞进行细胞培养,成功构建ILK-specific sh RNA慢病毒载体后对Panc-1细胞进行转染,荧光显微镜下观察,评估转染效率,然后通过Real time-PCR及Western Blot方法验证干扰基因片段的有效性。结果成功构建si RNA-ILK慢病毒载体并转染Panc-1细胞,荧光显微镜下观察可见转染效率达80%以上,RNAi靶点病毒转染的细胞组(KD)的ILK m RNA及蛋白表达明显低于空蛋白组(NC)及正常细胞组(CON,0.01)。结论成功构建RNA干扰ILK基因的慢病毒载体并转染胰腺癌细胞(Panc-1),验证了RNA干扰片段的有效性。     

Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells

Elevated phosphoethanolamine (PE) is frequently observed in MRS studies of human cancers and xenografts. The role of PE in cell survival and the molecular causes underlying this increase are, however, relatively underexplored. In this study, we investigated the roles of ethanolamine kinases (Etnk‐1 and 2) and choline kinases (Chk‐α and β) in contributing to increased PE in human breast and pancreatic cancer cells. We investigated the effect of silencing Etnk‐1 and Etnk‐2 on cell viability as a potential therapeutic strategy. Both breast and pancreatic cancer cells showed higher PE compared with their nonmalignant counterparts. We identified Etnk‐1 as a major cause of the elevated PE levels in these cancer cells, with little or no contribution from Chk‐α, Chk‐β, or Etnk‐2. The increase of PE observed in pancreatic cancer cells in culture was replicated in the corresponding tumor xenografts. Downregulation of Etnk‐1 with siRNA resulted in cell cytotoxicity that correlated with PE levels in breast and pancreatic cancer cells. Etnk‐1 may provide a potential therapeutic target in breast and pancreatic cancers.